Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bird Rock Bio
La Jolla, California, United Statesbirdrockbio.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Bird Rock Bio completed a Phase 1b multiple ascending dose trial for nimacimab in patients with non-alcoholic fatty liver disease (NAFLD) and diabetes or pre-diabetes. The trial showed no serious adverse events or early terminations due to adverse events. The company's lead candidate gerilimzumab (anti-IL-6 antibody) demonstrated safety and pharmacokinetics supporting low, infrequent dosing in clinical trials.
- Therapeutic areas
- GastroenterologyMetabolic DisordersNephrologyImmunologyRare Diseases
- Modalities
- Monoclonal antibodiesNegative allosteric modulating antibody (NAMA)
- Industry
- Biotech
02
Partnerships
Janssen Pharmaceuticals, Inc.GE HealthcareargenxGenor Biopharma
Beyond the preview
Go deeper on Bird Rock Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bird Rock Bio.